XML 23 R13.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Operating expense | 9 Months Ended
--- | ---
Sep. 30, 2022
Analysis of income and expense [abstract] |
Operating expense | Operating expense The following table provides the unaudited condensed consolidated interim statement of operations classification of the Company's total operating expense:
(in KUSD) | Three months ended September 30, |  | Nine months ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Cost of product sales | 1,295 |  |  | 502 |  |  | 4,090 |  |  | 623 |
R&D |  |  |  |  |  |  |
External costs (1) | 24,363 |  |  | 20,041 |  |  | 83,706 |  |  | 66,330 |
Employee expense (2) | 17,313 |  |  | 16,764 |  |  | 55,459 |  |  | 49,180 |
R&D expenses | 41,676 |  |  | 36,805 |  |  | 139,165 |  |  | 115,510 |
S&M |  |  |  |  |  |  |
External costs (3) | 8,236 |  |  | 7,973 |  |  | 26,406 |  |  | 18,989 |
Employee expense (2) | 8,611 |  |  | 9,072 |  |  | 26,470 |  |  | 27,188 |
S&M expenses | 16,847 |  |  | 17,045 |  |  | 52,876 |  |  | 46,177 |
G&A |  |  |  |  |  |  |
External costs (1) | 5,020 |  |  | 4,599 |  |  | 18,539 |  |  | 15,204 |
Employee expense (2) | 14,597 |  |  | 11,988 |  |  | 38,329 |  |  | 38,332 |
G&A expenses | 19,617 |  |  | 16,587 |  |  | 56,868 |  |  | 53,536 |
Total operating expense | 79,435 |  |  | 70,939 |  |  | 252,999 |  |  | 215,846 |
(1) Includes depreciation expense (2) Includes share-based compensation expense (3) Includes depreciation expense for Property, plant and equipment for the three and nine months ended September 30, 2022. All other depreciation expense was not material for the three and nine months ended September 30, 2022. All depreciation expense was not material for the three and nine months ended September 30, 2021.
The increase in Cost of product sales in the three and nine months ended September 30, 2022, was primarily associated with USD 0.8 million and USD 2.5 million of impairment charges, respectively. The USD 0.8 million of impairment charges was recorded during both the three months and nine months ended September 30, 2022 and was associated with inventory manufactured using the Company's existing process at a new facility that did not meet the Company's specifications. Additionally, impairment charges of USD 1.7 million was recorded during the nine months ended September 30, 2022 and related to the manufacturing of antibodies that did not meet the Company's specifications. In addition, Cost of product sales during the nine months ended September 30, 2022 increased due to a full nine months of sales activity in 2022 as compared to the same period in 2021 due to the commencement of ZYNLONTA sales in May 2021. As a result of FDA approval of ZYNLONTA in April 2021, the Company reversed KUSD 7,049 of previously recorded impairment charges during the nine months ended September 30, 2021, relating to inventory costs incurred for the manufacture of product prior to FDA approval. R&D external costs increased primarily as a result of higher chemistry, manufacturing and controls ("CMC") expense due to manufacturing activities to support the ADCT-212 program during the three and nine months ended September 30, 2022 as well as our continued clinical trials to expand the potential market opportunities for ZYNLONTA in earlier lines of therapy, advance Cami to support a BLA submission and build our pipeline. Employee expense increased for the nine months ended September 30, 2022 primarily due to higher contract labor expenses, wages and benefits and share-based compensation expense. The decrease in S&M expenses in the three months ended September 30, 2022 was primarily due to lower employee expense due to lower share-based compensation expense. External costs increased for the three months ended September 30, 2022 primarily as a result of higher expenses relating to the commercial launch of ZYNLONTA. The increase in S&M expenses in the nine months ended September 30, 2022 was primarily due to increased professional expenses relating to the commercial launch of ZYNLONTA. This increase during the nine months ended September 30, 2022 was partially offset by lower employee expenses primarily due to lower share-based compensation expense. The increase in G&A expenses in the three months ended September 30, 2022 was primarily due to higher employee expenses primarily related to USD 1.3 million of executive compensation associated with the CEO transition and higher share-based compensation expense. External costs for the three months ended September 30, 2022 was primarily due to higher professional expenses. The increase in G&A expenses in the nine months ended September 30, 2022 was primarily due to higher professional fees, including the fees associated with the license agreement entered into with MTPC. Employee expense for the nine months ended September 30, 2022 remained virtually flat at USD 38.3 million primarily as a result of lower share-based compensation expense offset by higher wages and benefits including USD 1.3 million of executive compensation associated with the CEO transition.

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of expenses by nature. [Refer: Expenses, by nature] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfExpensesByNatureExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration